Anastrozole: Uses, Evidence, Safety, Dosing, and Access

Anastrozole, also known by the brand name Arimidex, is an aromatase inhibitor used mainly in hormone-sensitive breast cancer care and sometimes discussed off-label in hormone protocols that are not FDA-approved uses. It lowers estrogen production by blocking aromatase 13. This guide summarizes evidence, safety, dosing concepts, interactions, and lawful access steps without giving personal medical advice.

What it is

Anastrozole is the generic name for Arimidex, a nonsteroidal aromatase inhibitor and small-molecule medication. It is used in hormone-sensitive breast cancer care, especially settings where lowering estrogen signaling is part of endocrine therapy 11.

Generic name, brand name, and drug class

Anastrozole is the generic name. Arimidex is a brand name. Its drug class is aromatase inhibitor, which means it acts on the aromatase enzyme involved in estrogen production 13.

Patients may also see anastrozole described as a nonsteroidal aromatase inhibitor, endocrine therapy, or part of an endocrine therapy backbone in oncology research. Several randomized trials in HR-positive and HER2-negative breast cancer studied endocrine therapy with drugs such as ribociclib, abemaciclib, palbociclib, fulvestrant, or everolimus 1 4 7 9.

How patients may see it described in oncology and hormone-care settings

In oncology, anastrozole is discussed in relation to hormone receptor-positive breast cancer, postmenopausal breast cancer, early breast cancer, and advanced breast cancer research 2 11. Outside oncology, it may be discussed in off-label hormone protocols that are not FDA-approved uses, but the supplied evidence set does not prove wellness, longevity, body-composition, or testosterone outcomes for those uses.

Mechanism of action

Anastrozole works by inhibiting aromatase, the enzyme that helps convert androgen hormones into estrogen. The clinical purpose of this estrogen-lowering effect depends on the diagnosis and care setting, so mechanism alone cannot decide whether the medication fits a person 13.

Aromatase and estrogen production

Aromatase is an enzyme involved in estrogen synthesis. By blocking aromatase, anastrozole reduces estrogen production, which is why it appears in endocrine therapy discussions for estrogen-sensitive disease 13.

Why estrogen lowering matters in hormone receptor-positive breast cancer

Hormone receptor-positive breast cancers can grow in response to hormone signaling. Randomized oncology trials in the supplied evidence set studied endocrine therapy strategies in HR-positive and HER2-negative breast cancer, including trials that used nonsteroidal aromatase inhibitor therapy as part of the treatment plan 3 6.

Why mechanism does not replace diagnosis, labs, or clinician oversight

Lowering estrogen can affect more than the target tissue. Bone mineral density, joint symptoms, menopausal symptoms, cardiovascular risk context, pregnancy risk, cancer history, and medication history all matter when a clinician weighs risks and benefits 13.

Evidence

Anastrozole is assigned Evidence Grade A in this page’s evidence system because the retrieved PubMed index count includes 339 human randomized controlled trials for the compound 14. That grade reflects the amount and design of research, not a personal recommendation.

Evidence grade rubric: A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

What the supplied human research covers

The supplied records include a phase 3 randomized clinical trial of neoadjuvant anastrozole, fulvestrant, or their combination in postmenopausal patients with estrogen receptor-rich and ERBB2-negative breast cancer 11. They also include randomized trials of endocrine therapy strategies and nonsteroidal aromatase inhibitor therapy in HR-positive and HER2-negative early or advanced breast cancer 1 2 3 6.

Several trials studied combination approaches rather than anastrozole alone. Examples include ribociclib plus endocrine therapy in early and advanced breast cancer, abemaciclib plus a nonsteroidal aromatase inhibitor in advanced breast cancer, and palbociclib-related endocrine switching in PADA-1 1 4 5 7 10.

What the evidence does not prove

This evidence set should not be stretched into claims about longevity, body composition, testosterone optimization, or general wellness. A high evidence grade in oncology research does not prove that off-label hormone protocols have the same benefit-risk profile.

The supplied records also include PHANTOM, a randomized, double-blind, placebo-controlled trial of anastrozole in pulmonary hypertension 12. That is research context; it should not be read as routine-care guidance for people outside that study setting.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-08.

Reported dosing ranges

Anastrozole dosing should be read as label- or study-reported information, not as instructions. The labeled adult dose listed in DailyMed is 1 mg taken orally once daily for the labeled breast cancer settings described in the label 13.

Oncology dosing and off-label hormone-protocol dosing are not interchangeable. Diagnosis, menopausal status, pregnancy risk, cancer history, bone health, other medications, and lab monitoring can all change the risk-benefit discussion 13.

Legal status

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-08. See the full legal-status tracker for every compound we follow.

Safety

Anastrozole can cause side effects and is not a casual hormone supplement. Labeling describes adverse effects and precautions that can include menopausal-type symptoms, joint symptoms, weakness, mood symptoms, bone mineral density loss, fracture risk, and pregnancy-related risk 13.

Common adverse effects to discuss with a clinician

Symptoms patients may need to discuss include hot flashes, joint pain or stiffness, fatigue or weakness, nausea, mood changes, and vaginal dryness or bleeding concerns, as reflected in labeling for anastrozole-containing products 13. Any new or severe symptom should be reviewed with the prescribing clinician.

Bone, joint, cardiovascular, and menopausal-symptom considerations

Because anastrozole lowers estrogen, bone health is a key safety issue. Labeling includes bone mineral density and fracture-risk considerations, so clinicians may consider baseline risk, prior fractures, other medicines, and monitoring when deciding whether it fits a patient 13.

Joint symptoms and menopausal-type symptoms can affect daily life. Cardiovascular history also belongs in the risk review, especially when anastrozole is being considered in a person with complex medical history or multiple medications 13.

When to seek urgent medical care

Urgent symptoms such as chest pain, trouble breathing, signs of a serious allergic reaction, severe weakness, fainting, or concerning neurologic symptoms should be treated as medical issues right away. The label should not be used as a substitute for emergency care when symptoms are severe 13.

Risks of unregulated supply

A product sold as “research use only” is not a patient medication. With unregulated supply, the practical risks include wrong identity, wrong strength, impurities, contamination, poor storage, and no clinician follow-up.

Interactions

Anastrozole can conflict with therapies that work against its intended estrogen-lowering effect. Estrogen-containing products are a key medication category to review with the prescriber or pharmacist 13.

Estrogen-containing therapies

Estrogen-containing therapies may interfere with the intended effect of anastrozole. This is especially important because Chia’s hormone-care education also covers estradiol and progesterone, but those services are not substitutes for oncology-directed anastrozole care 13.

Supplement, peptide, and hormone stacking

Supplements, peptides, hormone therapies, and cancer medicines should be reviewed together, not one at a time. The supplied evidence set includes combination oncology research with endocrine therapy, CDK4/6 inhibitors, fulvestrant, and everolimus, which shows why medication context matters 4 7 9.

If you are tracking hormones, inflammation markers, or metabolic labs, our guide to longevity labs can help you understand what labs can and cannot tell you. Lab results should not be used to self-adjust anastrozole.

Questions to bring to the prescriber or pharmacist

• Why is anastrozole being considered for my specific diagnosis or protocol?
• What benefits are realistic in this setting, and what evidence supports that use?
• What side effects should I watch for in the first few weeks and over time?
• How will bone mineral density, fracture risk, pregnancy risk, and labs be monitored?
• Could any estrogen-containing therapy, supplement, peptide, or hormone medication conflict with the plan?
• Who should I contact if I develop severe symptoms or need to stop a medication?

How to obtain it legally

Anastrozole should be handled through a medical process: clinician evaluation, diagnosis-specific decision-making, a prescription decision when appropriate, dispensing through a licensed pharmacy, and follow-up monitoring. Chia does not offer anastrozole; this page is education-only.

Clinician evaluation and diagnosis-specific decision-making

A clinician evaluation usually reviews the diagnosis, treatment goal, menstrual or menopausal status, pregnancy risk, cancer history, bone health, cardiovascular history, current medications, allergies, and relevant labs or imaging. A prescription requires a medical evaluation and is not guaranteed.

Prescription, licensed pharmacy, and follow-up monitoring

A licensed pharmacy is part of a medical supply chain with identity, labeling, storage, and dispensing standards. A research-chemical vendor is not a substitute for clinician evaluation, prescription decision-making, pharmacy dispensing, and follow-up.

Why Chia’s anastrozole coverage is education-only

At Chia, we cover anastrozole because patients often see it discussed near hormone care, oncology endocrine therapy, and off-label hormone protocols that are not FDA-approved uses. We do not offer anastrozole, and our hormone-related services should not be positioned as substitutes for oncology-directed care.

Chia does offer clinician-reviewed hormone-related care in our catalog, including estradiol, progesterone, and HRT for Women, when clinically appropriate. Chia medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door; compounded drugs are not FDA-approved.

If your question is broader hormone care rather than anastrozole specifically, our guides to progesterone and healthy aging may be useful starting points. If anastrozole is being considered for cancer care, stay with your oncology team for that decision.

Keep reading

Hormone Health

Side Effects of Estrogen and Progesterone: What to Expect and When to Call a Clinician

Hormone Health

Progesterone: What It Is, Evidence, Safety, Dosing, and How Treatment Works

Hormone Health

Estradiol: Uses, Evidence, Safety, Dosing, and How Treatment Works